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 2 
Abstract: 24 
During infection with hepadnaviruses besides the infectious agent a high number of 25 
subviral particles without nucleocapsids are produced, which are able to change the 26 
infection dramatically. In addition, it was observed that the activation of the nuclear 27 
factor of activated T cells, regulated usually in cells of the immune system, was strongly 28 
influenced after infection. When primary duck liver cells were infected with purified 29 
virions of duck hepatitis B virus the activation of this factor was reduced in a similar 30 
way as it was achieved by inhibition of calcineurin, a cellular phosphatase necessary to 31 
control the factor, whereas the addition of subviral particles inhibited this reduction. It 32 
was found that the large surface protein of the virus was responsible for the reduced 33 
activity. Although this protein was embedded in similar amounts into the envelopes of 34 
both particles, only virions were able to inhibit the activity of the nuclear factor. An 35 
explanation of the different performances of the particles in primary duck liver cells 36 
apparently depends on the individual mode of insertion of the large surface proteins into 37 
the viral membrane. Furthermore, the nuclear factor of activated T cells could only be 38 
detected in liver sinusoidal endothelial cells, which was shown being attracted by virions 39 
but not by subviral particles. 40 
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INTRODUCTION 48 
 49 
Transcription factors of the family of nuclear factors of activated T cells (NFAT) 50 
are expressed in most cells of the immune system and play a crucial role at the 51 
transcription of cytokines and other gene products important for an immune answer (13, 52 
27). In this context, the activation of NFAT proteins caused by the T cell receptor-CD3 53 
complex of stimulated T cells as a presumption for the induction of cytokines was 54 
intensively studied (44). Soon, the close relationship of the regulation of NFAT by the 55 
calcium/calmodulin-dependent serine/threonine protein phosphatase 2B (now specified 56 
as phospho-protein phosphatase 3, also called calcineurin) was evident (29). De-57 
phosphorylation of NFAT was shown to be a necessary requirement for its translocation 58 
from the cytoplasm into the nucleus. For this reason, the NFAT signaling pathway was 59 
the target of immunosuppressive drugs like Cyclosporin A (CsA), which, after binding 60 
to the cellular chaperone-like protein cyclophylin A, inhibits the phosphatase-activity of 61 
calcineurin (54). 62 
Naturally, the members of the family of hepadnaviruses with the human hepatitis B 63 
virus (HBV) as prototype have found a way to avoid a strong immune attack of the host 64 
as a prerequisite for the establishment of a persistent virus infection (50). Therefore, the 65 
events during the first hours of an infection are certainly critical, which especially 66 
depends on the efficiency to avoid an activation of early immune factors like 67 
interleukin-2 as a key element for the stimulation of cytotoxic and helper T cells. In this 68 
connection, the demonstration was essential that the X protein of HBV was able to 69 
activate the responding NFAT molecule (38) as well as to regulate the intracellular 70 
calcium level (2). On the basis of these observations, activation of NFAT could have 71 
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vital consequences for the initiation of the immune answer against viral infections. An in 72 
vitro model was established where liver cells from duck embryos containing all other 73 
immunological active components like liver sinusoidal endothelial and Kupffer cells 74 
were present. The aim was to prove, whether the application of the virions of duck HBV 75 
(DHBV) or the so-called subviral particles (SVPs), usually existing in an about 1,000 76 
fold excess, differently influence the modulation of NFAT.  77 
 78 
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MATERIALS AND METHODS 96 
 97 
Cells and purification of virus. The preparation of embryonic primary duck liver 98 
cells (PDLCs) by digestion with collagenase and culturing conditions were the same as 99 
already described (6, 55). In addition, the purification of DHBV as well as SVPs from 100 
sera of duck carriers were performed as reported (6, 14), where the different viral 101 
entities were separated in a steep 0-40 % Urografin (3,5-diacetamido-2,4,6-tri-102 
iodobenzoic acid, Schering AG, Berlin, Germany) gradient diluted in GNTE buffer (0.2 103 
M glycine, 0.2 M NaCl, 0.02 M Tris, and 0.002 M EDTA, pH 7.5) followed by a flat self-104 
forming Urografin gradient with an initial concentration of 26.5 %. Alternatively, virus 105 
particles were obtained from the supernatants of LMH-D2 cells, originating from a 106 
chicken hepatoma cell line after the stable transfection with a DHBV-overlength 107 
genome (16, 32), which were maintained in D-MEM-F12 medium (GIBCO, Eggenstein, 108 
Germany) supplemented with 10 % FCS, 100 U/ml penicillin, 100 µg/ml streptomycin 109 
und 2mM glutamine at 37°C and 5 % CO2.  If not stated otherwise, PDLCs were infected 110 
with a multiplicity of infection (MOI) of 0.01. In some cases, cells were treated with 111 
1µM of CsA or alternatively with a mixture of 40nM phorbol myristyl acetate and 4µM 112 
ionomycin. 113 
Transfection of hepatoma cells and PDLCs. The human hepatoma cell line HuH-114 
7 was grown with 10 % fetal calf serum in D-MEM (GIBCO). Usually, transfection 115 
experiments were performed by the Ca3(PO4)2-method as described (8) using the 116 
mutants 1285C (synthesizing DHBV without the small surface protein [S]) and 1165A 117 
(synthesizing DHBV without the large surface protein [L]); both mutants were kindly 118 
provided by J. Summers (58). Further transfection experiments were carried out using 119 
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either the vector pSH107c, a kind gift of G.R. Crabtree, where the full length human 120 
NFAT cDNA (52) was subcloned into the eukaryotic expression vector pBJ5 (26) or the 121 
eukaryotic expression vector pRK5, where downstream of the CMV promoter the DNA 122 
fragments for the core (C) protein (pRK5-C) or L of DHBV3 (pRK5-preS) were 123 
introduced within the restriction sites NruI and NotI after PCR amplification. Cells were 124 
harvested 96 hours after plating for the analysis of protein expression. Transfection 125 
efficiencies were controlled after staining the cell nuclei using Hoechst 33342 126 
(Invitrogen, Karlsruhe, Germany) by a green fluorescence protein-expressing vector. 127 
The use of this combination revealed efficiencies of about 30 % in HuH-7 cells, whereas 128 
in pRK5-C-transfected cells only an efficiency of about 10 % was obtained. 129 
Transfections in PDLCs were only satisfactorily achieved by use of Fugene (Roche, 130 
Indianapolis, USA) instead of the Ca3(PO4)2-method. 131 
Quantification of DHBV and SVPs. The number of viral genome molecules as 132 
determined by dot blot hybridization was considered equivalent to the number of virions 133 
since viremic duck sera seem to contain very few defective genomes (31). Viral 134 
genomic equivalents and the number of SVPs were determined as described elsewhere 135 
(6). 136 
Detection of viral proteins. Viral proteins were examined in disrupted cells 137 
separated on 5 to 20 % polyacrylamide gradient gels (37) as described (6) or 138 
alternatively analyzed by indirect immune fluorescence using rabbit anti-C or anti-preS 139 
antisera followed by incubation with Alexa Fluor488-conjugated secondary antibody 140 
(46). Cell nuclei were counterstained using Hoechst 33342.  141 
Measurement of NFAT activity. The analysis of NFAT activation was carried out 142 
with 5 µg of the cis reporter vector pNFAT-Luc (Stratagene, LaJolla, USA), in which a 143 
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response element for NFAT is located upstream of a TATA box and a luciferase reporter 144 
gene (Fig. 1a, top). Control transfections performed with the pCIS-CK and pAP1-Luc 145 
plasmids (Stratagene) didn’t disclose any increase or decrease of luciferase activities 146 
over background levels and were for reason of clarity not shown. In general, liver cells 147 
were infected with DHBV for 4 h and directly thereafter transfected with pNFAT-Luc 148 
for 24 h using the FuGene method (Fig. 1a, bottom). Supplementary analyses, where 149 
NFAT-transfections were performed one day earlier or later, were less successful 150 
(Bruns, unpublished data). In accordance with the experimental flow chart (Fig. 1b) one 151 
day after infection/transfection the supernatant was replaced by fresh medium and 2 152 
days later cells were harvested, washed with phosphate-buffered saline, and disrupted 153 
according to the manufacturer's protocol. After binding of the de-phosphorylated NFAT 154 
to its response element the luciferase gene could be determined in a Microluminat 155 
luminometer (Berthold, Wildbad, Germany). Usually, the luciferase activities are shown 156 
as columns representing the means of three calculations and expressed as relative light 157 
units (RLU) or as percentage of 100 % unstimulated cells with vertical bars as standard 158 
errors. 159 
Analysis of PDLC sub-populations. For the detection of phagocytic activities of 160 
liver-specific macrophages (Kupffer cells) PDLCs were incubated one day after plating 161 
with a suspension of colloidal Indian ink in PBS for 10 min and analyzed by con-focal 162 
microscopy. In order to check the presence of liver sinusoidal endothelial cells (LSECs) 163 
fluorescein-conjugated acetylated low density lipoproteins (acLDL: Biodpy FL-acLDL 164 
or Alexa Fluor594-acLDL; Molecular Probes, Leiden, The Netherlands) were added to 165 
PDLC cultures one day after plating for 2 h, whereupon cells were examined by con-166 
focal microscopy (3, 5).  167 
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RESULTS 168 
 169 
DHBV and SVPs generate distinct NFAT activations in liver cells. The first 170 
experiments were performed to find out, whether the addition of virions of DHBV, 171 
SVPs, or both have an effect on the calcium/calmodulin-dependent pathway of NFAT. 172 
For this reason, virus particles were separated first over a 0-40 % Urografin gradient, 173 
which, equally like sucrose gradients, regularly leads only to a partial separation of virus 174 
particles because of similar densities and the high surplus of SVPs. Therefore, the 175 
isolated DHBV or SVP particles of the first gradient were divided further by use of two 176 
flat gradients of 26.5 % leading to the enrichment of DHBV at the bottom of one and of 177 
SVPs at the top of the other gradient (6, 14). The initial idea for designing this 178 
experiment was to find out, whether the enhancement of virus replication usually 179 
obtained after the application of SVPs (6) was caused by an increased release of calcium 180 
ions. Because of the difficulties of the exact measurement of calcium ions, we planned 181 
to determine it indirectly by calculation of NFAT, which will only be activated by 182 
calcineurin in the presence of calcium ions. According to protocol, PDLCs were mock-183 
infected, infected with DHBV with or without SVPs, or with SVPs alone and co-184 
transfected with pNFAT-Luc (Fig. 1). The measurements represented a certain basal 185 
level of constitutively active NFAT, which was regularly detected in uninfected liver 186 
cells (Fig. 2a and b, CO). In contrast, after infection with virions at MOI 0.01 a drastic 187 
reduction of the NFAT activity could be observed (Fig. 2a and b, DHBV). When in 188 
addition to the low amount of virions a high surplus of SVPs was added, the lower 189 
NFAT activity was moderately restored using the preparation of partially purified 190 
particles (Fig. 2a, DHBV+SVPs), but nearly fully re-established using the preparation of 191 
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highly purified virus particles (Fig. 2b, DHBV+SVPs). On the other side, the application 192 
of the empty particles alone didn't reveal a strong difference in comparison to the 193 
luciferase activity of uninfected cells (Fig. 2a and b, SVPs).  194 
NFAT inactivation by DHBV resembles the decrease caused by the inhibition 195 
of calcineurin with CsA. A further control was performed to certify the specific nature 196 
of NFAT modulation caused by the virus particles. Because of the known inhibiting 197 
activity of CsA for calcineurin, which is necessary for the nuclear translocation of 198 
dephosphrylated NFAT, we proved whether the addition of CsA was able to inhibit the 199 
activation of NFAT (Fig. 2c). The influence of CsA on NFAT was investigated in 200 
uninfected cells (CO), in cells infected with virions (DHBV), or empty particles (SVPs). 201 
The results demonstrated that an addition of CsA reduced the NFAT activity in 202 
uninfected PDLCs (CO) in a comparable manner (CO- versus CO+ = 58 %), as was 203 
achieved by virions without further treatment (CO- versus DHBV- = 64 %). The NFAT 204 
activation in PDLCs was even more reduced, when virions were supplied together with 205 
CsA (DHBV- versus DHBV+ = 43 %), whereas the inhibition of CsA on NFAT 206 
activation was weak after the application of SVPs (SVPs- versus SVPs+ = 20 %).  207 
NFAT inactivation is largely independent of the infectious dose. A strong 208 
inhibition of NFAT activation was already measured in PDLCs infected with low doses 209 
of virions. This outcome was unexpected and could only be explained, when NFAT 210 
modulation was induced not only by the viral input alone but also by the release of some 211 
additional cellular or viral factors after infection. The relatively short incubation time of 212 
four days before measuring the activation of NFAT also speaks in this favor, because at 213 
that time point there is only a few progeny of virions, which could only be detected by 214 
PCR analysis (Chang and Bruns, unpublished data). On the other side, an activation of 215 
 
 10 
input virus could not be ruled out. For clarification, whether viral input or output was 216 
able to influence the NFAT activation, an experiment was performed, where in PDLCs 217 
the infection was continuously increased (Fig. 3). Again, a strong reduction of the 218 
luciferase activity was observed, when every one hundredth cell obtained an infectious 219 
particle (MOI 0.01). In general, the measurements remained low, even when 10 fold and 220 
100 fold higher viral inputs per cell were applied (MOI 0.1 and 1), whereas a further 221 
increase (MOI 10) resulted in reduced inhibitions of NFAT activation. An explanation 222 
for the latter observation could be that after the addition of 10 purified virions per cell a 223 
contamination with SVPs could not be avoided anymore.  224 
NFAT is inactivated by the large surface protein of DHBV. Originally NFAT 225 
was identified in T cells as a key factor for the expression of cytokines, but there were 226 
expanding reports of NFAT activation in a wide range of other cells (28). We wanted to 227 
know whether hepatocytes are also competent to activate this factor. I was found that the 228 
application of pNFAT-Luc to different hepatoma cell lines disclosed, although less 229 
pronounced as in PDLCs, again a basic level of NFAT activation (Bruns, unpublished 230 
data). In the next experiment, HuH-7 cells were transfected with vectors responsible for 231 
the production of two DHBV mutants (58). The first one (1165A) with a stop codon 232 
inside the preS part of L (alteration of TG112G into TA112G) lead to the production of 233 
DHBV containing S only, whereas the second one (1285C) with a point mutation at the 234 
S start codon (alteration of AT162G into AC162G) resulted in the production of DHBV 235 
containing L only (Fig. 4a). Cultures of HuH-7 cells were transfected with increasing 236 
amounts (0 to 6 µg) of 1285C and decreasing amounts (6 to 0 µg) of 1165A in parallel 237 
together with 3 µg pNFAT-Luc. Thus, each cell culture was treated in total with 6 µg of 238 
the viral plasmids in various combinations and 3 µg of pNFAT-Luc for the measurement 239 
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of NFAT activation. The results revealed a gradual decrease of NFAT activition with the 240 
continuous increase of 1285C, but not with 1165A (Fig. 4b). This tendency could be 241 
confirmed after the application of 1285C or 1165A alone, where 1285C exhibited a 242 
maximal inhibition of the NFAT activity, whereas 1165A exhibited luciferase activities 243 
similar to control levels. Western blots performed in parallel demonstrated in cells the 244 
continuous increase or decrease of the proteins in correlation to the amounts of viral 245 
plasmid DNAs applied (Fig. 4c, left). Transfection with 1165A alone resulted in a 246 
secretion of particles (most probably SVPs), whereas this was not the case, when 1285C 247 
was used (Fig. 4c, right). In summary, the transfection experiments using DHBV 248 
without S or DHBV without L, gave a first clue that L could be responsible for the 249 
inhibition of NFAT activition. 250 
As both vectors, 1285C and 1165A, were able to synthesize C, but only NFAT-251 
inactivating virions contain a nucleocapsid and not SVPs, the next experiments were 252 
performed with vectors responsible for the expression of either C or L alone. The study 253 
was carried out again in HuH-7 cells, but now with the protein expression vector pRK5 254 
encoding either L or C of DHBV together with pNFAT-Luc. Because of the relative low 255 
measurements of luciferase activities acquired with these vectors all three parallel 256 
experiments are displayed. Identical amounts of cells were used for transfections, which 257 
were verified at the end of the experiment by amido black staining of the PVDF 258 
membrane (Fig. 5a). The cells were transfected alternatively with pRK5-C or pRK5-259 
preS for the expression of C (lanes 3) or L (lanes 4), respectively. As controls cells 260 
transfected with pRK5 (lanes 2), untreated cells (lanes 5), cells treated with CsA (lanes 261 
6) or transfected with the GFP-containing vector (lanes 1) were introduced; the latter 262 
was used to calculate the transfection efficiencies, which were about 30 % in this 263 
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experiment. The Western blots with anti-C (Fig. 5b) or anti-S antisera (Fig. 5c) revealed 264 
similar viral protein expression in the experiments I and II, whereas experiment III 265 
expressed slightly more L and less C. In all three experiments, it was apparent that the 266 
application of pRK5-preS, responsible for the expression of L, lead to an inhibition of 267 
NFAT activation, which were similar to measurements observed in CsA-treated cells 268 
(Fig. 5d). Instead cells, which were transfected with pRK5 or the C-expressing vector 269 
resulted in some stimulation of NFAT activation, similarly as was demonstrated for the 270 
GFP-containing plasmid. A possible explanation for the latter effects could be the 271 
presence of some internal sequences similar to the NFAT response element. 272 
NFAT initiates migrations of core and large surface proteins towards the 273 
nucleus. Transfection experiments were carried out in HuH-7 cells with pRK-C and 274 
pRK-preS to analyze the intracellular locations of the translated products by indirect 275 
immune fluorescence. Naturally, both DHBV proteins appear broadly distributed as dot-276 
like structures in the cytoplasm (Fig. 6a and b); the decision whether the small amounts 277 
of C, detectable in association with the stained nuclei, was localized within or above the 278 
nucleus could not be made unmistakably (Fig. 6a). On the other side, though only in 279 
about 1 % of positive cells, these small nuclear dots were strongly enlarged and nearly 280 
exclusively enriched within the nucleus, when the cells were co-transfected with 281 
pSH107c for the parallel production of NFAT proteins (Fig. 6c). In some cases C was 282 
concentrated near the nuclear pores (Fig. 6c, arrows). Another form of convergence of 283 
the antigen via NFAT was observed with an anti-preS antibody in cells co-transfected 284 
with pRK-preS and pSH107c; in this case, the preS proteins were strongly focused 285 
within small areas around the nucleus in about 10 % of stained cells, but never inside the 286 
nucleus (Fig. 6d); in other cells various stages of enrichment around the nucleus could 287 
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also be detected (not shown). These actions were reversible, when at the same time CsA 288 
was added (Fig. 6e and f). At present, we interpret these findings to mean that NFAT 289 
molecules were able to transport bound viral antigens towards the nucleus; but only C, 290 
probably because of its minor size and/or the presence of a nuclear localization signal 291 
(42, 43), was able to pass the nuclear membrane. 292 
Detection of NFAT in LSECs of a duck liver. As our protocol allowed the 293 
preparation of total PDLCs, we wanted to know which other liver cells could be detected 294 
associated with hepatocytes. We found that, similarly as described for the human liver 295 
(17), parenchymal (hepatocytes) as well as non-parenchymal cells were obtained in a 296 
ratio of about 60 to 40 % (Fig. 7b), where the latter could be furthermore subdivided 297 
into about 70 % Kupffer cells, 30 % LSECs, and 3 % fat storing (Ito) cells (17). By use 298 
of colloidal Indian ink and acLDL the biological activities against foreign material, 299 
phagocytosis of ink particles by Kupffer cells (Fig. 7a) and uptake of Fluorescein-300 
stained acLDL by LSECs (Fig. 7c), could be demonstrated. Further co-immune 301 
fluorescence studies with anti NFATc and acLDL uptake revealed an association of 302 
NFAT proteins with LSECs in vitro and in vivo (3, 5, Maenz and Bruns, unpublished 303 
data).   304 
Co-localization of NFAT and viral proteins was discovered in LSECs. Our first 305 
hypothesis was to identify NFAT molecules in hepatocytes, which represent the final 306 
targets for hepadnaviruses. The additional observation of NFAT activation in hepatoma 307 
cell lines increased our suspicion that NFAT molecules could be detected in the same 308 
cells, which were also infected by DHBV. Unexpectedly this was not the case. 309 
Moreover, NFAT was found in LSECs and the question came up again, similarly as 310 
already proposed (3), which role these cells play during infection.  311 
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Earlier experiments have shown that LMH-D2 cell cultures lead to production and 312 
release of viral progeny consisting of virions, nucleocapsids (NCs), and SVPs in a ratio 313 
of about 1 : 1 : 10-100, i.e. the high excess of SVPs usually found after infections in vivo 314 
(ducks) or in vitro (PDLCs) was reduced about 10 to 100 fold in such cultures; this 315 
tendency strongly facilitated the efficiency of virus purification (Bruns, unpublished 316 
data). Virus particles were obtained from the supernatants of LMH-D2 cells and 317 
thereafter separated, contrary to the usual protocol, first by a flat self-forming Urografin 318 
gradient with the initial concentration of 26.5 % and thereafter by the conventional 0-40 319 
% Urografin gradient. After the first ultracentrifugation step DHBV particles (virions 320 
and NCs) were collected from the bottom and SVPs from the top. The efficiency of 321 
separation was proved by the analysis of the surface proteins of virions and SVPs in a 322 
Western blot (Fig. 8a). The high density of NCs enabled the successive separation from 323 
virions using a 0 to 40 % gradient; both subunits could easily be discriminated by DNA 324 
dot blots of the fractions collected after ultracentrifugation being positive for NCs and 325 
virions (Fig. 8b, left), but negative for SVPs (Fig. 8b, right). Thereafter, purified virions, 326 
NCs, and SVPs were added to PDLC cultures. In order to visualize also the uptake of 327 
virus particles into non-parenchymal cells the virus dose was increased to 500 particles 328 
per cell. After an adsorption time of 2 h acLDL was added and the cells were incubated 329 
for further 2 h before fixation and treatment of cells with anti-viral antibodies (anti-330 
DHBc for the detection of virions and NCs, anti-DHBpreS for the detection of virions 331 
and SVPs). Only in cells incubated together with acLDL and virions a co-staining could 332 
be identified using anti-DHBc and (possibly due to the presence of contaminating SVPs) 333 
to a lesser extent using anti-DHBpreS antisera (Fig. 8e, middle); no co-staining could be 334 
visualized in cells, where NCs (Fig. 8e, left) or SVPs (Fig. 8e, right) were added. These 335 
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findings let us suggest that virions are associated, at least in the beginning of an 336 
infection, with LSECs, whereas no SVPs or NCs could be detected. 337 
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 360 
DISCUSSION 361 
 362 
One key event of the regulated transcription response to immune stimuli is the 363 
calcium/calmodulin-dependent signal cascade leading to the activation of NFAT (54). 364 
The NFAT signaling pathway is also influenced by a number of viruses including 365 
human immunodeficiency virus (33, 45), African swine fever virus (18, 48, 49), Rhesus 366 
monkey rhadinovirus (10), hepatitis C virus (1), and human herpesvirus 8 (53), which 367 
either induce a cellular state permissive for viral infection and replication or suppress 368 
immune detection and clearance of the virus. For herpes simplex virus it was shown that 369 
the nuclear translocation and activation of NFAT was blocked (56). In this case, it could 370 
be demonstrated that virus binding was not sufficient to inhibit the nuclear translocation 371 
of NFAT, but that entry of the virion and early gene transcription were required. 372 
Moreover, it was detected that a consequence of blocking the NFAT import was the 373 
reduction in NFAT-dependent transcriptional activation from the interleukin-2 promoter. 374 
All in all, these examples include both stimulatory and inhibitory interventions acting at 375 
various levels of the cascade.  376 
Besides the immune modulating role of T cell activation, the range of NFAT target 377 
genes is expanding to differentiation of non-immune cells (9, 28). Hence, it could be 378 
explained for the HBV-transfected hepatocytes that the viral X protein was able to 379 
activate NFAT by a CsA-sensitive pathway (38) and regulate intracellular calcium level 380 
(2). In addition, it was shown that NFAT1-C repressed the transcriptional activity of the 381 
enhancer II and the pregenomic promoter (EnII/Cp) of HBV. As the NFAT1-C 382 
responsive site GGAGA was located at the position of the nucleotides 1603 to 1618, the 383 
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HBx-driven transcriptional activation of the EnII/Cp was cancelled in a dose dependent 384 
manner (40). So far, all the experiments with hepadnaviruses were performed by 385 
transfection experiments of hepatoma cell lines. Here, we show for the first time that 386 
activation of NFAT is diminished by the application of virions during an acute infection 387 
of PDLCs, similarly, as can be seen after the addition of the specific calcineurin 388 
inhibitor CsA. The specificity was be proved by different experiments using purified 389 
DHBV with or without purified SVPs for infection, where a high surplus of SVPs over 390 
virions neutralized the inactivation of NFAT. On the first sight this observation seemed 391 
to be contradictory to findings exhibiting an enhancement, when  PDLCs were infected 392 
with low MOI and contained at the same time high amounts of SVPs (6). However, 393 
these studies performed in vitro do certainly not reflect the local situation present in the 394 
liver of a host with an effective immune system at the early phase of an infection. 395 
However, the phenomenon of enhancement could play a role later-on starting with the 396 
second round of infection. 397 
Whether activation or inhibition of NFAT is the result of a regulation at the level of 398 
the intracellular calcium balance in infected cells, similarly as described for the spike 399 
protein of mouse hepatitis virus (35), the envelope protein gp120 of human 400 
immunodeficiency virus (11), or the X protein of HBV (2, 38), still remains an open 401 
question. Our investigation demonstrated that the activation of NFAT could again be 402 
recovered from its suppressed state, when SVPs were added imitating an event, where 403 
the calcium influx into the cytoplasm was elevated by treatment of cells with ionophores 404 
(Bruns, unpublished data). 405 
So far it is not clear, whether the activation of other transcription factors like NFκB, 406 
similarly as was shown e.g. for human immunodeficiency virus and herpesvirus 8 (53), 407 
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plays a role during the infection with DHBV, but the strong reduction of NFAT 408 
activation at a low infection dose has undoubtedly an implication during the acute 409 
infection in vivo in as far as to avoid a recruitment of immune cells like T lymphocytes 410 
or macrophages because of the lack of cytokine stimulation. This would imply that at the 411 
beginning of an infection and at a moment, when only a few SVPs are present, more 412 
infectious agents would escape the destruction by immunological active cells and could 413 
explain, why it is possible to infect ducklings with DHBV using extreme low virus doses 414 
(31). Later, with the presence of higher amount of virus particles, especially SVPs, the 415 
immune system will then be mobilized as usual, but now with the possible consequence 416 
of enhancement or inhibition depending on virus burden (6, 34). Interestingly, it seems 417 
that the hepadnaviral L, responsible for the first interaction with the host-cell receptor 418 
and for many other biological activities during the viral life cycle (4, 6, 7, 12, 15, 20, 22-419 
25, 30, 36, 39, 41, 51, 57, 59, 60) is also the most important candidate of NFAT 420 
inactivation and for some time our main concern was how L-containing virions were 421 
able to reduce NFAT activity in one case, whereas L-containing SVPs did not. Our 422 
observations of the diverse fashion of activation could be possibly explained with the 423 
different orientation of the molecules within the envelope of both particles, as our data 424 
indicated that this protein is usually located on the outside of virions, whereas in SVPs 425 
most of the proteins are hidden in the interior obviously as a consequence of 426 
phosphorylation, although it was demonstrated that phosphorylation of L does not 427 
influence the infectivity (19, 21). Alternatively, the variable presentation of L in virions 428 
and SVPs could also result in different pathways for both particles within parenchymal 429 
and/or non-parenchymal cells of the liver (3). At least, some possible interactions 430 
between NFAT and viral products could be demonstrated by co-transfection 431 
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experiments, where a strong intracellular migration was initiated for C and L of DHBV 432 
in the presence of NFAT, which could again be blocked by CsA.  433 
One detail needs further consideration, as it became obvious that reduction of 434 
NFAT inactivation was similarly strong, when infections were performed with low as 435 
well as higher virus doses. Certainly, by the nature of whole liver cell preparation with 436 
its difficulties for total segregation into single cells the prediction of virus dose per cell 437 
can only be a rough estimation, which also ignores the detail that nearly half of the cell 438 
number is not of the hepatocellular type. Moreover, the low transfection efficiency of 439 
about 10 % of total liver cells will also minimize the probability that one cell in a culture 440 
got both virus by infection and pNFAT via transfection. Under these circumstances, a 441 
direct influence of virions on NFAT activity is rather unlikely. Therefore, we believe 442 
that other factors released from infected cells could be involved. Infection studies 443 
revealed that besides SVPs also the post-translationally modified core protein, the e-444 
antigen of DHBV, is secreted in high amounts within the first days of infection (Bruns, 445 
unpublished data). Here, we could demonstrate that an inhibition of NFAT activation by 446 
purified SVPs can be excluded. For this reason, the objective of our next studies will 447 
concentrate on purified e-antigen, which is now available (47). 448 
Taken together, these data indicate that inactivation of NFAT was caused by the 449 
virions but not by the SVPs of DHBV, which could have substantial consequences 450 
during the early state of an infection of a host, where only a few number of virions is 451 
available and the number of SVPs not high enough to influence the infection (6, 34). 452 
 453 
 454 
 455 
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 480 
FIGURE LEGENDS 481 
 482 
Fig. 1. Protocol for the measurement of NFAT activation in PDLCs. (a) Scheme, 483 
modified from the manufacturer’s instruction manual, of the plasmid pNFAT-Luc 484 
containing the response element for NFAT, the TATA box, and the Luciferase gene 485 
(top). Binding of the de-phosphorylated trans-activator TA (NFAT) to the NFAT 486 
response element after infection of PDLCs with DHBV and co-transfection with 487 
pNFAT-Luc (bottom). (b) Experimental flow chart displaying the time points of various 488 
treatments of PDLCs between plating and harvest. 489 
Fig. 2. Modification of the NFAT activity in PDLCs by virions or SVPs of DHBV. 490 
(a) PDLCs were either mock-infected (CO), infected with partly purified virions at MOI 491 
0.01 (DHBV) or infected together with partly purified 10 SVPs/cell (DHBV+SVPs), or 492 
treated with 10 SVPs/cell alone (SVPs). (b) Repetition of the experiment described 493 
above, but this time highly purified virions and SVPs were used. (c) PDLCs, either 494 
uninfected (CO), infected with highly purified virions at MOI 0.01 (DHBV), or treated 495 
with highly purified 10 SVPs/cell (SVPs) were alternatively mock-treated (-) or treated 496 
with 1 µM of the calcineurin-inhibitor CsA (+).  497 
Fig. 3. Independence of NFAT activation by the titer of infectious virus. PDLCs 498 
were transfected and either mock-infected (MOI 0) or infected with different amounts of 499 
purified virions (MOI 0.01 to MOI 10). 500 
Fig. 4. Analysis of NFAT activation after transfections with DHBV-S- and DHBV-L-501 
mutants. (a) Scheme according to Summers and co-workers (58) demonstrating the point 502 
mutations within the viral DNA to obtain either the DHBV mutant 1165A by insertion 503 
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of a stop codon at the carboxy terminus of the preS part of L (left) or to obtain the 504 
DHBV mutant 1285C by destruction of the start codon for S (right). (b) HuH-7 cells 505 
were transfected with pNFAT-Luc and the plasmids 1285C and 1165A in the 506 
concentrations shown. Quantification of NFAT activation showed a continuous 507 
reduction of luciferase activities with increasing amounts of 1285C and at the same time 508 
decreasing amounts of 1165A. (c) Examinations by Western blot with an anti-S 509 
antiserum, performed in parallel, revealed a gradual increase of S equivalent to the 510 
added amounts of 1165A, whereas only a minor difference of L was noticed after an 511 
increased application of 1285C (left). A lower release of virus particles into the 512 
supernatants was observed with increased accumulation of 1285C (right). The first line 513 
represents DHBV-positive duck serum (DS) as control; the positions of the viral 514 
envelope proteins P18 (S) as well as P36 (L) and its cleavage product P28 (L) are shown 515 
on the right. 516 
Fig. 5. Effect of the proteins C and L of DHBV on NFAT activation. HuH-7 cells 517 
were transfected three times in parallel (Experiments I to III) using an expression vector 518 
without any insert (pRK5) or a vector containing alternatively the viral C (pRK5-C) or L 519 
(pRK5-preS) as inserts. A green fluorescent protein (GFP)-containing plasmid was used 520 
for the calculation of the transfection efficiencies. Mock-treated cells (CO) and cells 521 
treated with CsA provided further controls. Cells were harvested after 4 days and 522 
divided into two portions: one half was used for measuring the luciferase activities (d), 523 
the other half was analyzed by Western blot using first antibodies against the core (b) 524 
and then against the surface proteins of DHBV (c); finally, the blot was stained with 525 
Amido Black to compare the total amount of cellular proteins (a). The marker proteins 526 
for the estimation of the molecular weights are shown on the left side, whereas a 527 
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DHBV-positive duck serum on the right side was applied to demonstrate the positions of 528 
the viral surface proteins. Note that only CsA-treatment or transfection with the L-529 
expression vector lead to the inhibition of NFAT activation (d). 530 
Fig. 6. Indirect immune fluorescence of HuH-7 cells for the demonstration of the 531 
localizations of DHBV proteins after NFAT production. Cells were transfected with 532 
pRK5-C or pRK5-preS for the expressions of viral C (a, c, e) and L proteins (b, d, f) 533 
alone (a, b) or in combination with NFAT proteins expressed by the vector pSH107c (c-534 
f). As controls, CsA was added to the co-transfected cell cultures (e, f). Arrowheads 535 
show possible concentrations of C around nuclear pores.  536 
Fig. 7. Analysis of parenchymal and non-parenchymal subsets of duck liver cells. A 537 
total PDLC preparation was examined three days after cultivation by confocal 538 
microscopy demonstrating the partition into hepatocytes (rich in vacuoles) and non-539 
parenchymal cells (b). Addition of colloidal ink was used to visualize the phagocytic 540 
activities of Kupffer cells distributed over the whole culture (a), whereas the specific 541 
uptake of Fluorescein-labeled acLDL served for the recognition of LSECs mainly found 542 
within the area of non-parenchymal cells (c). 543 
Fig. 8. Investigation of the association of LSECs with NCs, virions, or SVPs of 544 
DHBV. (a) Virus particles were separated first in a self-forming Urografin gradient of 545 
26.5 % and collected either from the bottom-fractions, where virions and NCs were 546 
concentrated, or the top-fractions containing the SVPs; the amount of particles were 547 
calculated and checked in a Western blot before further separation (note that here an 548 
anti-DHBpreS antiserum was used, which could not recognize NCs). (b) A steep 549 
Urografin gradient was then used to separate the collected DHBV sample into virions 550 
and NCs, which were both detected by measuring the DNA content per fraction in a dot 551 
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blot (left), or to prove the purity of the SVPs containing no DNA (right). (c) The isolated 552 
particles (NCs, virions, SVPs) were then applied to PDLC cultures and checked after an 553 
adsorption time of 4 h with an anti-DHBc antiserum (red) for the discovery of NCs and 554 
virions (upper row) or with an anti-DHBpres antiserum (red) for the recognition of 555 
virions and SVPs (lower row); note that co-immune fluorescence with acLDL (green), 556 
which was added 2 h before harvest, was only detectable with purified virions (middle 557 
pictures). 558 
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